Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial

PURPOSE: This study aimed to assess the antitumor activity and safety of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: In this single-center, single-arm, phase 2 trial, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhanjie, Wu, Bian, Peng, Gang, Xiao, Guixiang, Huang, Jing, Ding, Qian, Yang, Chengzhang, Xiong, Xingao, Ma, Hui, Shi, Liangliang, Yang, Jinsong, Hong, Xiaohua, Wei, Jielin, Qin, You, Wan, Chao, Zhong, Yi, Zhou, Yan, Zhao, Xueyan, Leng, Yangming, Zhang, Tao, Wu, Gang, Yao, Min, Zhang, Xiaomeng, Yang, Kunyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662919/
https://www.ncbi.nlm.nih.gov/pubmed/35766967
http://dx.doi.org/10.1158/1078-0432.CCR-22-0666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662919/
https://www.ncbi.nlm.nih.gov/pubmed/35766967
http://dx.doi.org/10.1158/1078-0432.CCR-22-0666

Ejemplares similares